1.. INTRODUCTION
================

According to the central dogma of molecular biology, biological information flows in one direction from DNA to RNA to protein \[[@R1]\]. The logical consequence of this dogma is that non-coding RNA (ncRNA) has no intrinsic value, however over 90% of transcriptional output in eukaryotes are non-coding \[[@R2]\]. Therefore it is perhaps unsurprising that microRNAs (miRNAs) were unknown to science up until just over 20 years ago, and not formally recognized until 2001 \[[@R3]\]. Now we realize that miRNAs play key regulatory roles in nearly every aspect of biology including cell differentiation, developmental timing, cell proliferation, apoptosis, organ development, metabolism, and hematopoiesis \[[@R4]\]. Approximately, 2/3 of all human genes are regulated directly by miRNAs \[[@R5]\], and now over 2500 human miRNAs have been identified \[[@R6]\]. The importance of miRNAs in cancer is suggested as most of them are located at cancer-associated genomic regions \[[@R7]\]. Furthermore, miRNAs are aberrantly expressed in all cancers including lymphoma \[[@R8]\]. There are many causes of dysfunctional expression in cancer including epigenetic deregulation, chromosomal aberrations, aberrant expression of transcription factors that regulate promoters of miRNAs, and factors that change miRNA biosynthesis or function \[[@R9]\].

Lymphoma is a cancer of the lymphatic system (B and T cells) representing the fifth most common cancer type worldwide and affecting more than a million people. The incidence of non-Hodgkin's lymphoma (NHL) has increased74% in the US, between 1976 and 2001, and since then is the fifth most common form of death from cancer \[[@R10]\]. In this review we consider the role of miRNAs in lymphomas, their use as biomarkers and their potential as therapeutics.

2.. ROLE OF MIRNAS IN LYMPHOPOIESIS
===================================

Hematopoietic stem cells (HSC) must balance their pluripotency whilst at the same time responding to lineage determining signals. This process is tightly regulated by a network of intrinsic and extrinsic stimuli, transcription factors, signaling pathways, cytokines, growth factors, and other molecular components. MiRNAs can target many of these as well as more generally determining HSC fate, differentiation state, self-renewal ability and function, apoptosis levels, and the balance of lymphoid and myeloid progenitor cells \[[@R11]\].

MiRNAs play a crucial role in hematopoiesis as demonstrated by the deletion of *Dicer1,* which severely inhibited peripheral CD8^+^ development as well as reducing numbers of CD4^+^ cells which when stimulated displayed increased apoptosis rates and low proliferatation \[[@R12]\]. However, when *Dicer1* was deleted in CD34^+^ HSCs an increase in apoptosis occurred along with reduced hematopoietic ability \[[@R13]\], and when deleted in early B cell progenitors the pro to pre B cell transition was blocked as a result of *miR-17\~92*targeting of BIM which could be rescued by BCL2 expression \[[@R14]\].

The first study to look at miRNA involvement in lymphocyte development was in 2004, and demonstrated that *miR-223,* *miR-181* and *miR-142* were highly expressed in B-cells, and that HSCs expressing ectopic *miR-181*significantly increased the numbers of B-cells and cytotoxic CD8+ T-cells in recipient mice \[[@R15]\]. *miR-181*can also regulate levels of CD69, BCL2 and TCRα during T cell development \[[@R16]\], and is responsible for T-cell receptor sensitivity \[[@R17]\]. *miR-155*deletion in mice made them immunodeficient, with B cells producing lower immunoglobulin levels after antigen treatment, and T cells producing reduced levels of IFNG and IL2. Both of these effects were mediated by regulation of PU.1 \[[@R18]\]. Activation of B cells or CD4+ T cells *in vitro*can up-regulate *miR-155*, whilst deletion of this miRNA in activated B cells reduces TNF and lymphotoxin levels as well biasing T cell differentiation towards the T~h~2 phenotype \[[@R19]\].

Both *miR-155* and *miR-181* are key regulators of germinal centre (GC) B-cell differentiation \[[@R20]\]. Deletion of *Dicer1*in activated B cells reduces GC B-cell formation and consequent B-cells express higher levels of BIM \[[@R21]\]. GC B-cells are characterized by CD10, HGAL, BCL6, and LMO2 expression of the lack of the activated B-cell markers XBP1 or PRDM1/BLIMP1 \[[@R22]\]. *miR-155* directly regulates levels of both HGAL and Rhotekin 2 \[[@R23]\], whilst the *miR-30* family, *miR-9* and *let-7a*, all target BCL6 and PRDM1/BLIMP1 \[[@R24]\]. *miR-223* controls expression of LMO2 \[[@R25]\], and *miR-125b* of PRDM1/BLIMP1 and IRF4 \[[@R26]\]. *miR-155* also regulates PU1 and CD10 modulating activated B-cell formation through NF-kB \[[@R27]\], and *miR-125a/b* can regulate TNFAIP3 promoting activation of NF-kB \[[@R28]\]. The *miR-17-92*cluster is another essential regulator of lymphopoiesis. Targeted deletion of these miRNAs causes blockage of pro- to pre-B cell pathway as a result of BIM inhibition \[[@R29]\]. Members of the *miR-17-92*cluster can also target other key immunomodulatory components including PP2A, PTEN and PRKAA1 \[[@R29],[@R30]\]. Pro- to pre-B cell development is also regulated by *miR-34a*and *miR-150*via modulation of FOXP1 \[[@R31]\], and MYB respectively \[[@R32]\].

3.. B-CELL LYMPHOMAS
====================

As under physiological conditions there is a clear involvement of miRNAs in malignant lymphomagenesis in general. For example, *Dicer1*deletion in a murine myc-lymphoma model decreased the incidence of lymphoma coupled with a change to very early B-cell precursor stage of diesase \[[@R33]\]. Similarly in a p53-null model, *Dicer1*deletion reduced lymphomagenesis and conferred prolonged survival to the mice \[[@R34]\]. Below we discuss the involvement of miRNAs in the most common types of lymphoma.

3.1. Diffuse Large B-cell Lymphoma (DLBCL)
------------------------------------------

Diffuse large B-cell lymphoma (DLBCL) represents the most common lymphoid malignancy with an incidence of about 3 per 100,000 people and accounts for nearly 40% all lymphoid tumors \[[@R35]\]. DLBCL was one of the first lymphomas to be linked with aberrant miRNA expression, in particular the observation that *miR-155*is highly expressed in this malignancy \[[@R36]\]. Indeed, forced over-expression of this miRNA in mice results in the development of a high grade B-cell lymphoma similar to DLBCL \[[@R37]\]. Further experimentation has shown that this oncogenicity is mediated by *miR-155*targeting of SHIP1 and C/EBPβ \[[@R38]\]. When *miR-155*was expressed in an inducible manner, although mice developed lymphoma, when the stimulus was removed the tumor quickly disappeared and after one week mice had no measurable disease at all \[[@R39]\]. *In vitro, miR-155*expression suppresses the growth-inhibition of BMP2/4 and TGF-β1 in DLBCL cells via SMAD5 inhibition \[[@R40]\]. It can also regulate the PI3K-AKT pathway via targeting of PIK3R1 \[[@R41]\]. Interestingly it has been demonstrated that SHIP1 is differentially expressed in the two major molecular subtypes of DLBCL (i.e. activated B cell-like (ABC) and germinal center B cell-like (GC)) \[[@R42]\]. This is consistent with identified differences in *miR-155*expression between GC- and ABC-type DLBCL \[36b, 36c\]. Moreover, CD10, associated with GC-type DLBCL \[[@R43]\], and constitutive NF-κB expression, the hallmark of ABC-type DLBCL \[[@R44]\], are linked through the *miR-155/PU.1*pathway \[[@R27]\]. When mice were inoculated with U2932, an ABC-type DLBCL cell line treatment with exogenous *miR-34a*reduced tumor growth via targeting Foxp1 \[[@R45]\], a molecule associated with ABC-type DLBCL \[[@R22]\]. *miR-34a*is a well described tumor suppressor miRNA that is closely connected with the p53 network in solid tumors \[[@R46]\], and a positive feedback loop exists whereby p53 induces *miR-34a*expression and in turn *miR-34a*activates p53 through SIRT1 inhibition \[[@R47]\].

Over-expression of the *miR-17\~92*cluster in a Eµ-myc model resulted in increased aggressiveness of lymphoma development \[[@R48]\]. The MYC/*miR-17-92/*E2F circuit was shown to be responsible for this affect \[[@R49]\], as MYC up-regulates the *miR-17-92*cluster which in turn targets E2F1, whilst conversely pro-proliferative E2F3 regulates the *miR-17-92*cluster \[[@R50]\]. *miR-19*has been identified as the key oncogenic component of the *miR-17-92*cluster and can activate the Akt-mTOR pathway in the Eµ-myc model through PTEN antagonization resulting in the promotion of cell survival \[[@R51]\] (Fig. **[1](#F1){ref-type="fig"}**).

3.2. Follicular Lymphoma (FL)
-----------------------------

Despite follicular lymphoma (FL) being the most common indolent lymphoma, there are relatively few studies that have investigated miRNA expression in this disease. In the first of these, the levels of 153 miRNAs were measured in 46 FL samples and compared with DLBCL cases or normal lymph nodes \[[@R52]\]. Shortly afterwards, our group measured the expression levels of 464 miRNAs in 18 cases of FL and 80 cases of DLBCL \[[@R53]\]. In this publication we reported that the levels of six miRNAs (*miR-223, miR-217, miR-222, miR-221, let-7i*and *let-7b*) were differentially expressed between cases of FL that underwent high grade histological transformation compared to those that did not. More recently, the *miR-17\~92*cluster has been identified as a useful diagnostic differentiator between the potentially confounding diagnosis of GC-DLBCL and FL (grade 3) \[[@R54]\]. Another study compared FL with nodal marginal zone lymphoma (NMZL) \[[@R55]\], and yet another with follicular hyperplasia \[[@R56]\]. This latter study identified miRNAs associated with FL patients that responded to PACE chemotherapy, as well as showing that p21 and SOCS2 were regulated by *miR-20a/b*and *miR-194*in FL cell lines.

Although \>90% of FL cases have the t(14;18) translocation, a minority do not. Interestingly, a recent study identified 17 miRNAs that were differentially expressed between these diseases \[[@R57]\].

3.3. Mantle Cell Lymphoma (MCL)
-------------------------------

Although relatively rare, mantle cell lymphoma (MCL) is a particular aggressive lymphoma and the prognostic outcome of patients is poor. Several studies have looked at miRNA expression in MCL \[[@R58]\]. The loss of potential miRNA target sites for *miR-15/16*and members of the *miR-17-92*cluster in the 3\'UTR of CCND1 are proposed to contribute to the characteristic Cyclin D1 over-expression in MCL \[[@R59]\]. Indeed, over-expression of *miR-17\~92*cluster members are correlated with high MYC expression in aggressive MCL \[58c\]. Similarly a high proliferation gene signature \[58d\], and activation of the PI3K/AKT pathway, as well as inhibition of chemotherapy-induced apoptosis are found in MCL cell lines \[[@R60]\]. PHLPP2, a key regulator of the PI3K/Akt pathway, has been shown to be targeted by the *miR-17-92*cluster along with PTEN and BIM in MCL \[[@R61]\]. Inhibition of *miR-17-92*expression in a xenotransplant model of MCL inhibited PI3K/Akt pathway and caused decreased tumor growth. Also the inhibition of *miR-29*was demonstrated to activate CDK4/CDK6 in MCL, as well as acting as a potential prognostic marker for this disease \[58a\].

3.4. Burkitt Lymphoma (BL)
--------------------------

The hallmark of Burkitt lymphoma (BL) is the MYC-IgH (t(8;14)) translocation that results in over-expression of the MYC oncogene. Mice with a mutation in a *miR-155*binding site of the 3´-UTR of the AID gene display increased levels of these translocations \[[@R62]\]. MYC regulates, and in turn itself is regulated by a large number of miRNAs. This results in a complex regulatory loop that is intimately involved in lymphomagenesis \[[@R63]\]. Indeed it has been suggested that MYC over-expression in BL cases without the t(8;14) translocation can be explained by miRNA deregulation \[[@R64]\]. In addition to a functional role, miRNAs could also facilitate classification of the group of B-cell lymphomas with intermediate features between DLBCL and BL \[[@R64]\].

3.5. Hodgkin Lymphoma (HL)
--------------------------

Ribonucleoprotein chromatin immunoprecipitation (RIP-ChIP) was used to look at the involvement of miRNAs Hodgkin lymphoma (HL) HL cell lines \[[@R65]\]. They found an over-representation of genes associated with cell proliferation, apoptosis and the p53 pathway. Elsewhere JAK2 was demonstrated to be regulated by *miR-135a,*and that over-expression increased apoptosis and decreases cell growth via Bcl-xL inhibition in HL cell lines \[[@R66]\]. Furthermore they observed that patients with low *miR-135a* had significantly poorer prognostic outcome. Inhibition of *let-7* and *miR-9*reduced the levels of PRDM1/BLIMP1 in HL cell lines preventing plasma cell differentiation \[[@R67]\]. In another study *miR-9*was shown to target Dicer and HuR in HL. Inhibition of *miR-9*led to a decrease in cytokine production and a reduced ability to attract inflammatory cells \[[@R68]\]. Ectopic administration of a *miR-9*antagomir caused to decreased tumor growth in a xenotransplant model.

3.6. Other B-cell Lymphomas
---------------------------

A number of studies have looked at the role of miRNAs in mucosa-associated lymphoid tissue (MALT) lymphoma. For example, a 27-miRNA signature was identified that could distinguish between gastric DLBCL and MALT lymphoma \[[@R69]\]. This study proposed that the transformation from gastritis to MALT lymphoma is regulated epigenetically by methylation of *miR-203,*leading to the proposition that ABL1 might be a useful druggable target for this malignancy \[[@R70]\]. In another study five miRNAs (*miR-150, miR-550, miR-124a, miR-518b*and *miR-539)*were identified as being differentially expressed in MALT lymphoma compared to gastritis \[[@R71]\]. High E2A levels were found to correlate with increased *miR-223*expression in gastric MALT lymphoma \[[@R72]\]. Finally, a miRNA signature of splenic marginal zone lymphoma (SMZL) cases was reported \[[@R73]\].

4.. T-CELL LYMPHOMAS
====================

Compared to their B-cell counterparts, very little is known about miRNA expression in T-cell lymphoma. Our group provided the first functional evidence for miRNAs in T-cell lymphomas in a study on Sézary syndrome (SzS), a rare aggressive primary cutaneous T-cell (CD4(+)) lymphoma \[[@R74]\]. We demonstrated that *miR-342*plays an important pathogenic role in SzS by targeting RANKL which was associated with the protection of SzS cells from apoptosis. The identity of several of the miRNA we identified as being aberrantly expressed have subsequently been validated by other groups since \[[@R75]\]. More recently, further mechanistic insights into the role of miRNA in SzS showed that the widespread deficiency of PTEN observed in SzS might be in part explained by the dysregulation of *miR-21*, *miR-106b*, and *miR-486* \[[@R76]\].

Mycosis fungoides (MF) is a common, indolent primary cutaneous T-cell lymphoma (CTCL), with rare, more aggressive variants. A minority of the MF cases may undergo transformation associated with poor prognosis. Our group have also performed profiling studies on tumor stage MF \[[@R77]\], as well as in cutaneous anaplastic large cell lymphoma (cALCL) \[[@R78]\]. As a result of these, a qRT-PCR based classifier (*miR-155, miR-203*and *miR-205)*has been proposed, able to distinguish between the various forms of cutaneous T-cell lymphomas and related benign disorders \[[@R79]\]. Importantly, both a training (n = 90) and a blinded test (n = 58) cohorts were used in this study. Besides its role in B-cell development, *miR-150*also regulates NK cells via Myb targeting \[[@R80]\], as well as other T-cell subsets through NOTCH3 inhibition \[[@R81]\]. Transfection of *miR-150*into NK/T cell lymphoma cell lines increased apoptosis and decreased cell proliferation. These effects were mediated via DKC1 and AKT2targeting, and caused a decrease in BIM, p53 and phospho-AKT levels. In addition, over-expression of *miR-155*and *miR-21* was shown to activate the PI3K-Akt pathway in NK/T-cell lymphomas \[38c\]. Also, over-expression of *miR-122*in CTCL induced AKT phosphorylation linked to a decreased sensitivity to chemotherapy-induced apoptosis, as well as inhibiting p53 expression \[[@R82]\].

5.. MIRNAS AS BIOMARKERS OF LYMPHOID MALIGNANCIES
=================================================

The first demonstration that miRNAs could be useful as diagnostic biomarkers came from the 2002 groundbreaking publication of Calin and co-workers*,*who made the connection between the frequently deleted 13q14 locus, and the down-regulation of the *miR-15a/16* cluster that is encoded within this region in chronic lymphocytic leukaemia (CLL) patients \[[@R83]\]. Two years later, miRNAs were first demonstrated as prognostic biomarkers in lung cancer patients \[[@R84]\]. Since then, the speed of miRNA cancer biomarker discovery has been quite astonishing with over 9600 publications to date (source: Pubmed search (15/03/15) string= "(microRNA AND cancer) AND (prognosis OR diagnosis OR biomarker)"). The potential of miRNAs as cancer (diagnostic) biomarkers is obvious as particular miRNA expression profiles can distinguish cancers according to diagnosis and developmental stage of the tumor to a greater degree of accuracy than traditional gene expression analysis, even discriminating between cancers that are poorly separated histologically \[[@R85]\]. This ability is especially attractive to the field of B-cell lymphomas, a group of more than 35 recognized neoplasms \[[@R86]\] classified largely on the basis of immunohistochemical staining patterns, that are often challenging to accurately diagnose \[[@R87]\]. The usefulness of molecular methods to complement traditional morphological classifications in B-cell lymphoma is exemplified by DLBCL, where gene expression profiling has led to the identification of least two distinct subtypes that are prognostically and mechanistically very different, and respond differently to treatment \[[@R42],[@R88]\] (Table **[1](#T1){ref-type="table"}**).

5.1. miRNAs As Non-invasive Biomarkers of B-cell Lymphoma
---------------------------------------------------------

An additional feature of miRNAs that make them attractive candidates as cancer biomarkers is that they are much more stable than other RNA species and, as a result, can be purified and measured easily in routinely prepared formalin-fixed paraffin embedded (FFPE) biopsy material \[36b\] and biological fluids such as blood or its derivatives (sera, plasma) \[[@R89]\]. The standard protocol for many cancers (including lymphoma) diagnosis remains the histopathological inspection of tumor material obtained by invasive biopsy; a procedure that is rather frequently expensive, uncomfortable and sometimes risky for patients. Therefore there has been great interest in the field of circulating nucleic acids in blood as non-invasive cancer biomarkers \[[@R90]\]. An additional benefit of blood-based testing is the capability to perform screening and repeat sampling on patients undergoing therapy, or monitoring disease progression allowing for the development of a personalised approach to cancer patient management. Unlike other RNA molecules, the vast majority of which are degraded by high levels of RNases found in the blood \[[@R91]\], miRNAs seem to be stable in the blood and are surprisingly resistant to fragmentation by either chemical or enzymatic agents \[[@R92]\].

In 2007 we first reported the presence of miRNAs in the blood of lymphoma patients \[[@R93]\] and in 2008 demonstrated the up-regulation of *miR-155*and *miR-210*in the blood (sera) of DLBCL patients compared to healthy controls, as well as the prognostic potential of *miR-21* \[[@R94]\], an observation validated independently some years later \[[@R95]\]. In addition to confirming the up-regulation of *miR-155*in DLBCL sera, another study also reported up-regulation of *miR-15a, miR-16*and *miR-29c,* and down-regulation of *miR-34a* \[[@R96]\]. A third study, this time in plasma rather than sera, observed reduced levels of *miR-*92 that varied in response to chemotherapy in DLBCL, FL and T-cell non-Hodgkins lymphoma patients \[[@R97]\]. Similarly, plasma levels of *miR-92a* have been proposed as diagnostic/prognostic biomarkers for multiple myeloma (MM) \[[@R97],[@R98]\].

In HL patient, plasma levels of *miR-494* and *miR-1973* were identified as indicators of both relapse and interim therapy response \[[@R99]\]. In addition, plasma *miR-221* has been found to be a good diagnostic and prognostic marker for extranodal natural killer T-Cell NK/Tcell lymphoma \[[@R100]\].

Clearly although results are very preliminary, the ability of miRNAs to act as non-invasive biomarkers of B-cell lymphomas is a promising prospect (Table **[1](#T1){ref-type="table"}**).

6.. MIRNAS AS PREDICTIVE MARKERS OF RESPONSE AND POTENTIAL THERAPEUTIC USES
===========================================================================

Recently, miRNA profiling of different B-cell lymphomas has been shown to be useful beyond the mere classification of different lymphoma entities. For example, a 6-gene model combined with the international prognostic index (IPI) and with a three-miRNA expression signature could predict patients' outcome in a series of 176 uniformly treated DLBCL cases, and correlated the results to survival \[[@R101]\]. More recently, Iqbal and collaborators have found a predictive miRNA signature in DLBCL, associated with R-CHOP response failure. This signature included high expression levels of *miR-155,*as we have previously reported \[[@R53]\]. Furthermore, *in vitro* overexpression of *miR-155* sensitized cells to AKT inhibitors, suggesting a novel treatment option for resistant DLBCL \[[@R102]\].

Indeed, probably the most promising clinical aspect of miRNAs is their potential as novel therapeutic molecules, either as a tool to modulate target genes associated with disease, or by correcting dysfunctional expression of the miRNAs themselves. The former approach is particularly attractive because a single miRNA can be used against multiple components of a disease pathway or even against the pathway in its entirety \[[@R103]\]. There are two major strategies to therapeutically modulate deregulated miRNAs in cancer; the first to use miRNA mimics to restore physiological levels of miRNAs that are down-regulated for example tumor suppressor miRNAs such as *miR-34 or let-7.*A second strategy is to use inhibitors of over-expressed miRNAs for example directed against so-called oncomirs such as *miR-21*or *miR-155* \[[@R39],[@R104]\].

There now exists a wealth of *in vivo* animal evidence that have provided the proof-of-principle of the therapeutic efficacy of miRNAs in disease; however, at present all but a couple of these studies remain at the pre-clinical stage. Translating these results into the clinic need first addressing a few major issues, such as the effective targeting of therapy (e.g. tissue-specific delivery, dosage and pharmacodynamics), as well as safety concerns (e.g. off-target effects, RNA-mediated immunostimulation and the use of viral vectors etc.). Indeed, although a number of strategies to deliver miRNA in experimental models have been used in research, clinically applicable tools for gene delivery are limited and currently are focused on retroviral-based or adenoviral-based vectors.

In addition to viral vector-based gene therapy, synthetic miRNA has also been used in gain-of-function assays. These miRNA mimics are small, chemically modified RNA molecules that resemble endogenous mature miRNA molecules that are commercially available \[[@R105]\]. By the use of formulated synthetic miRNA, the therapeutic potential of exogenous *miR-34a* against human multiple myeloma cells *in vitro* and *in vivo* has been successful in preclinical models. This favorable outcome is a proof of concept that supports the use of formulated *miR-34a* based treatment strategies in patients \[104a\]. MiRNA mimics have no vector-based toxicity; therefore, if their delivery agents do not cause side effects over long-term use, they can be a promising therapeutic approach for tumors.

That said, this is an area very much still in its infancy that is almost certain to flourish in the near future as the field matures, and promises to add to the current battery of therapies available to clinicians in the continual fight against lymphoma.

7.. CONCLUSION AND FUTURE DIRECTIONS
====================================

Over the last years, a number of studies have underlined the key role that miRNAs have in lymphoma, both in B-cell and in T-cell malignancies. They interfere with multiple pathways involved in cell cycle, tumor growth and apoptosis, acting as tumor suppressor or oncogenes. Interestingly, different lymphoma subtypes have distinct miRNAs expression profiles. Their ability to improve histological classification and their stability in body fluids make them ideal biomarkers. Further studies and clinical trials are needed to confirm the prognostic and predictive power of miRNAs, as well as to test the miRNAs and their blocking molecules as a therapeutic approach for lymphoma.
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###### 

Examples of deregulated ncRNAs in relationship with their potential as biomarkers in various lymphoma types.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Lymphoma                                                                                                                                                                                 miRNA                                             Biomarker Type   Sample Source   Cohort Size   *P-*value   Reference     
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------- ---------------- --------------- ------------- ----------- ------------- -------------
  DLBCL                                                                                                                                                                                    *miR-155miR-210*\                                 D                Serum           60            43          0.009\        \[[@R94]\]
                                                                                                                                                                                           *miR-21*                                                                                                     0.02\         
                                                                                                                                                                                                                                                                                                        0.04          

  *miR-21*                                                                                                                                                                                 D, P                                              Serum            62              50            \< 0.001    \[[@R106]\]   

  *miR-15a, miR-16-1, miR-29c, miR-34a, miR-155*                                                                                                                                           D                                                 Serum            75              77            \< 0.05     \[[@R96]\]    

  *miR-155*                                                                                                                                                                                PR                                                Biopsy           79              \-            0.0008      \[[@R102]\]   

  *miR-18a*\                                                                                                                                                                               P                                                 Biopsy           176             \-            0.038\      \[[@R101]\]   
  *miR-181a*\                                                                                                                                                                                                                                                                               0.026\                    
  *miR-222*                                                                                                                                                                                                                                                                                 0.004                     

  *SNORA48, miR-106b\*, miR-106b, miR-1181, miR-124, miR-1299, miR-25\*, miR-33b\*, miR-432, miR-551b\*, miR-629, miR-652, miR-654-3p, miR-671-5p, miR-766, miR-877\*, miR-93, miR-93\**   PR                                                Biopsy           116             \-            0.03        \[[@R107]\]   

  FL                                                                                                                                                                                       *miR-9, miR-9\*, miR-301, miR-338, miR-213*       D                Biopsy          46            7           NA            \[[@R52]\]

  *miR-223, miR-217, miR-222, miR-221, let-7i, let-7b*                                                                                                                                     P                                                 Biopsy           7               11            \< 0.05     \[[@R53]\]    

  MCL                                                                                                                                                                                      *miR-29*                                          P                Biopsy          30            \-          0.04          \[58a\]

  HL                                                                                                                                                                                       *miR-494, miR-1973, miR-21*                       D                Plasma          42            20          0.004\        \[[@R99]\]
                                                                                                                                                                                                                                                                                                        0.007\        
                                                                                                                                                                                                                                                                                                        \< 0.0001     

  *miR-135a*                                                                                                                                                                               P                                                 Biopsy           89              \-            0.04        \[[@R66]\]    

  *miR-21, miR-30e, miR-30d, miR-92b*                                                                                                                                                      P, PR                                             Biopsy           29              \-            \< 0.001    \[[@R108]\]   

  MALT                                                                                                                                                                                     *miR-150, miR-550, miR-124a, miR-518b, miR-539*   D                Biopsy          NA            NA          \< 0.001      \[[@R71]\]

  SzS                                                                                                                                                                                      *miR-150, miR-191, miR-15a, miR-16*               D                PBMCs           36            12          0.04          \[[@R109]\]

  *miR-21*\                                                                                                                                                                                P                                                 PBMCs            23              \-            0.03\       \[75b\]       
  *miR-214*\                                                                                                                                                                                                                                                                                0.004\                    
  *miR-486*                                                                                                                                                                                                                                                                                 0.0038                    

  MF                                                                                                                                                                                       *miR-155*\                                        D                Biopsy          19            12          0.014\        \[[@R77]\]
                                                                                                                                                                                           *miR-92a*\                                                                                                   0.001\        
                                                                                                                                                                                           *miR-93*                                                                                                     0.001         

  NK/T-cell                                                                                                                                                                                *miR-221*                                         D, P             Plasma          79            37          0.038         \[[@R100]\]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ncRNA, non-coding RNA; miR, microRNA; SNOR, small nucleolar RNAs; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle-cell lymphoma; HL, Hodgkin lymphoma; MALT, mucosa-associated lymphoid tissue lymphoma; SzS, Sézary syndrome; MF, mycosis fungoides; NK/T-cell, extra-nodal natural killer T-Cell (NK/T-cell) lymphoma; D, Diagnostic Biomarker; P, prognostic Biomarker; PR, Predictive of response to treatment Biomarker; MV, microvesicles; PBMCs, peripheral blood monuclear cells; NA, not available.
